Home > Insider Trading > Filing (0001209191-18-054531)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1515673	Ultragenyx Pharmaceutical Inc.	RARE	Pharmaceutical Preparations (2834)	272546083

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1598426	William Aliski	C/O Ultragenyx Pharmaceutical Inc. 60 Leveroni Court Novato CA 94949		Yes	No	No	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Acquisiton	2014-02-05	84,970	$0.00	121,900	No	4	C	Indirect	By trust
Common Stock	Disposition	2015-05-12	10,500	$68.65	111,400	No	4	S	Indirect	By trust
Common Stock	Disposition	2015-05-27	2,000	$85.94	109,400	No	4	S	Indirect	By trust
Common Stock	Disposition	2015-07-27	400	$122.58	109,000	No	4	S	Indirect	By trust
Common Stocki	Disposition	2018-04-19	650	$53.97	108,350	No	4	S	Indirect	By trust
Common Stock	Disposition	2018-10-08	6,000	$73.38	102,350	No	4	S	Indirect	By trust

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	C	Indirect	By trust
No	4	S	Indirect	By trust
No	4	S	Indirect	By trust
No	4	S	Indirect	By trust
No	4	S	Indirect	By trust
No	4	S	Indirect	By trust

Reported Derivative Transactions

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Series A Preferred Stock	Disposition	2014-02-05	266,343	$0.00	84,970	$0.00

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
0			No	4	C	Indirect

Reported Non-Derivative Holdings

Sec. Name	Remaning Holdings	Nature of Ownership	Explanation
Common Stock	72,610	Direct

Footnotes

The number of shares of Common Stock reported reflects the automatic conversion of shares of Series A Preferred Stock into Common Stock on a 1-for-3.1345 basis immediately prior to the closing of the Issuer's initial public offering.
These shares are held in a trust for the benefit of the reporting person's spouse and children. The reporting person's spouse and nephew are trustees of the trust.
The sales reported on this Form 4 were effected pursuant to a trading plan adopted by the Reporting Person's trust pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended.
Each share of Series A Convertible Preferred Stock was convertible into Common Stock at any time and automatically converted into Common Stock on a 1-for-3.1345 basis immediately prior to the closing of the Issuer's initial public offering of Common Stock and had no expiration date.
The number of underlying shares of Common Stock reported in Column 7 reflects the automatic conversion of shares of Series A Preferred Stock into Common Stock on a 1-for-3.1345 basis immediately prior to the closing of the Issuer's initial public offering.